C. Edwards

The BILAG-2004 index is sensitive to change for assessment of SLE disease activity

I. Bruce, C. Gordon, D. Isenberg, 2009, Rheumatology.

Effectiveness of Belimumab After Rituximab in Systemic Lupus Erythematosus

C. Gordon, D. Isenberg, B. Griffiths, 2021, Annals of Internal Medicine.

Valuing Health Gain from Composite Response Endpoints for Multisystem Diseases.

Antoni B. Chan, I. Bruce, C. Gordon, 2022, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Immunological indicators of coeliac disease activity are not altered by long‐term oats challenge

C. Feighery, N. Kennedy, A. Davies, 2013, Clinical and experimental immunology.

The temporal relationship between cancer and adult onset anti-transcriptional intermediary factor 1 antibody–positive dermatomyositis

J. Lamb, I. Bruce, B. Harrison, 2018, Rheumatology.

Comparison of Responsiveness of British Isles Lupus Assessment Group 2004 Index, Systemic Lupus Erythematosus Disease Activity Index 2000, and British Isles Lupus Assessment Group 2004 Systems Tally

C. Gordon, D. Isenberg, B. Griffiths, 2022 .

Outcomes of children born to mothers with systemic lupus erythematosus exposed to hydroxychloroquine or azathioprine

I. Bruce, C. Gordon, M. Khamashta, 2022, Rheumatology.

The use of Systemic Lupus Erythematosus Disease Activity Index-2000 to define active disease and minimal clinically meaningful change based on data from a large cohort of systemic lupus erythematosus patients

I. Bruce, C. Gordon, D. Isenberg, 2010, Rheumatology.

The BILAG-2004 systems tally—a novel way of representing the BILAG-2004 index scores longitudinally

I. Bruce, C. Gordon, D. Isenberg, 2012, Rheumatology.

Patient-centred standards of care for adults with myositis

J. Lamb, P. Machado, P. Kiely, 2017, BMC Rheumatology.